MA-VERACODE
21.4.2022 17:52:05 CEST | Business Wire | Press release
Veracode , a leading global provider of application security testing (AST) solutions, today announced it has been positioned as a Leader for the ninth consecutive time in the 2022 Gartner Inc. Magic Quadrant for Application Security Testing1 . The company is the only vendor recognized as a Leader every single year since the report was first published.
“Since Veracode launched in 2006, we have played a significant role in shaping the application security market,” said Sam King, Chief Executive Officer at Veracode. “To be recognized as a Leader every single year, in our opinion, is a validation of our rich heritage, continued innovation, and strong vision for the future of software security and development. With cybersecurity taking center stage for enterprises across all industries, we’re proud to be a trusted partner for our customers, enabling them to bring development and security teams together to build and deliver secure software at the speed that business demands.”
According to Gartner, Veracode is recognized for its completeness of vision and ability to execute in the AST market. The company has also been identified in Gartner Peer Insights™ as a Customers’ Choice for Application Security Testing 2 , which is based on feedback and ratings from independent customer reviews.
Brian Roche, Chief Product Officer at Veracode, said, “The rapid acceleration of digital transformation, combined with increased software supply chain complexity and new cybersecurity regulations, means software security has never been more vital. Over the past year, we have focused heavily on geographical expansion with our European Region instance, and delivered new technologies, such as API Scanning, that address some of our customers’ biggest pain points. Our own platform evolution initiatives give us a deep understanding and appreciation for the challenges many of our customers face in their own digital transformation journeys, improving our capacity to function as a trusted advisor.”
Veracode’s comprehensive platform offers multiple testing types and integrates into popular development tools through a frictionless interface, providing a 360-degree view of application security posture. The company credits its position in the report to a laser focus on the transformation of its platform, launch of API Scanning, authentication management in dynamic analysis, and its static analysis and software composition analysis (SCA) capabilities Veracode’s SCA product uses natural language processing and machine learning to accurately identify vulnerabilities from multiple sources in open-source libraries. Through this proprietary process, the Veracode solution has identified hundreds of previously undetected vulnerabilities in open-source libraries in the last year alone.
In 2021, Veracode launched the Veracode European Region instance to support EU data residency requirements. The underlying platform has been leveraged to underpin Veracode’s much-anticipated FedRAMP instance, which will be introduced in the coming months.
“It’s a truly exciting time for Veracode. We have just announced a significant growth investment from TA Associates with a $2.5 billion valuation—a major milestone in our 16-year history—and look forward to a year of continued innovation and accelerating growth. We remain tirelessly committed to our mission of securing the software that powers our customers’ businesses, and our continued position as a Leader is, in our opinion, a testament to the passion and dedication of our team around the world,” King added.
To download a complimentary copy of the full 2022 Gartner Magic Quadrant Report, visit: https://info.veracode.com/2022-gartner-mq-gated.html
To learn more about application security from Veracode, please visit: https://www.veracode.com/products
1
Gartner, “Magic Quadrant for Application Security Testing” by Dale Gardner, Mark Horvath, Dionisio Zumerle, 18 April 2022.
2
Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, 27 October 2021.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner and Peer Insights are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com , on the Veracode blog and on Twitter .
Copyright © 2022 Veracode, Inc. All rights reserved. All other brand names, product names, or trademarks belong to their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005866/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom